Scarica l'app Stockscreener
15.81
2.33%
0.36
Dopo l'orario di chiusura:
15.33
-0.48
-3.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.45
Aprire:
$15.45
Volume 24 ore:
483.11K
Relative Volume:
0.41
Capitalizzazione di mercato:
$1.31B
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-8.6868
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
+1.74%
1M Prestazione:
-13.56%
6M Prestazione:
+50.86%
1 anno Prestazione:
+97.13%
Intervallo 1D:
$15.31
$15.84
Intervallo di 1 settimana:
$14.62
$16.73
Portata 52W:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
15.81 | 1.28B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3%Here's What Happened - MarketBeat
Aug Final Week: How does E2open Parent Holdings Inc. correlate with NasdaqMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can EyePoint Pharmaceuticals Inc expand its profit marginsTrade Exit Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Trade Recap: What is the long term forecast for EyePoint Pharmaceuticals Inc stockWeekly Profit Summary & High Accuracy Investment Signals - baoquankhu1.vn
(EYPT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Insider Trends: What are analysts price targets for EyePoint Pharmaceuticals IncGDP Growth & Safe Entry Momentum Tips - baoquankhu1.vn
Volatility Watch: Is EyePoint Pharmaceuticals Inc stock overvalued or fairly pricedMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Aug Reactions: Will URTY stock go up in YEARJuly 2025 Rallies & Weekly High Momentum Picks - baoquankhu1.vn
EyePoint (EYPT) Issues Stock Options to New Employees - GuruFocus
EyePoint, Inc. (EYPT) Stock Analysis: Exploring the 127.80% Potential Upside in a Challenging Market - DirectorsTalk Interviews
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards - Quiver Quantitative
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpTime to Buy? - MarketBeat
Equities Analysts Issue Forecasts for EYPT Q3 Earnings - MarketBeat
EyePoint, Inc. Provides Corporate Update and Anticipated Milestones for 2026 - VisionMonday.com
Responsive Playbooks and the EYPT Inflection - Stock Traders Daily
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Weekly Recap & AI Driven Price Predictions - ulpravda.ru
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.6%Here's Why - MarketBeat
Will EyePoint Pharmaceuticals Inc. stock remain a Wall Street favoriteGrip and Outsole Review & road comfort picks for daily use - Улправда
EyePoint, Inc. (EYPT) Stock Analysis: Exploring the 111% Upside Potential Amidst Strategic R&D - DirectorsTalk Interviews
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutMarket Performance Report & Safe Entry Point Identification - ulpravda.ru
How EyePoint Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Gainers & Real-Time Volume Analysis Alerts - ulpravda.ru
Aug Ideas: Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikes2025 Year in Review & Safe Investment Capital Preservation Plans - Улправда
Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Value Summary & High Conviction Buy Zone Alerts - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock continue dividend increasesMarket Volume Report & Entry Point Confirmation Alerts - ulpravda.ru
Ramiro Ribeiro Sells 42,544 Shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock - MarketBeat
Eyepoint Insider Sold Shares Worth $727,319, According to a Recent SEC Filing - marketscreener.com
EyePoint Chief Medical Officer Sells All Common Stock Holdings - TradingView — Track All Markets
EyePoint, Inc.Common Stock (NQ: EYPT - FinancialContent
Mizuho reiterates Outperform rating on EyePoint stock with $33 target By Investing.com - Investing.com Canada
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target - Investing.com Australia
Mizuho reiterates Outperform rating on EyePoint stock with $33 target - Investing.com
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target By Investing.com - Investing.com India
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data - Investing.com
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data By Investing.com - Investing.com South Africa
EyePoint, Inc. Advances DURAVYU in Pivotal Phase 3 Trials for Wet AMD and DME with Key Milestones Expected in 2026 - Quiver Quantitative
Uveitis Treatment Market to Reach US$ 1,258.35million | CAGR - openPR.com
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - GlobeNewswire
PRN_FinancialWrapper | PR NewswireEyePoint, Inc.Common Stock (Nasdaq:EYPT) Stock Quote - FinancialContent
Is EyePoint Pharmaceuticals Inc. stock dividend yield sustainable2026 world cup usa national team round of 32 playmakers set piece tactics winner prediction statistical analysis - ulpravda.ru
EYPT (EyePoint) Days Payable : 1,883.28 (As of Sep. 2025) - GuruFocus
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise? - AD HOC NEWS
Institutional Investors in EyePoint, Inc. (NASDAQ:EYPT) See US$67m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
What drives EyePoint Pharmaceuticals Inc PV3B stock priceSell Signals and Alerts & Top Analyst Picks Available for Free - earlytimes.in
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1%Here's What Happened - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Understanding the Setup: (EYPT) and Scalable Risk - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):